Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... has been combined with other novel agents such as lenalidomide , histone deacetylase inhibitors and growth factors in the hope ...

    Research Article last updated 05/14/2013 - 2:48pm.

  3. Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional

    ... value of IPSS-R subgroups for LFS and OS. Treatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an ...

    Research Article last updated 08/07/2013 - 9:18am.

  4. Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes

    ... of neoplastic cells. Thalidomide and its derivative lenalidomide have been proposed for the treatment of MDS because of their ...

    Research Article last updated 01/03/2013 - 9:57am.

  5. Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

    ... The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be ... Associated Drug(s):  Lenalidomide Phase:  Phase 1 ...

    Clinical Trial last updated 04/29/2016 - 10:40am.

  6. Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome

    ... This phase II trial studies how well lenalidomide and eltrombopag olamine works in treating patients with ... in low or intermediate myelodysplastic syndrome. Lenalidomide may stimulate the immune system in different ways and stop cancer ...

    Clinical Trial last updated 04/28/2016 - 10:10am.

  7. Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

    ... research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment formyelodysplastic syndrome (MDS) or ... to determine the safety and efficacy of the bortezomib and lenalidomide investigational combination. This drug combination has been used ...

    Clinical Trial last updated 04/28/2016 - 10:20am.

  8. Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    ... This randomized phase III trial studies lenalidomide to see how well it works with or without epoetin alfa ... patients with myelodysplastic syndrome and anemia . Lenalidomide may stop the growth ofmyelodysplastic syndrome by blocking blood ...

    Clinical Trial last updated 04/27/2016 - 9:59am.

  9. Myelodysplastic syndromes: an update on molecular pathology.

    ... hypomethylating drugs, immunomodulatory agents such as lenalidomide , and immunosuppressive drugs aimed at reversing the specific ...

    Research Article last updated 10/11/2011 - 5:58pm.

  10. Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

    ... Purpose:  The drugs, lenalidomide , bortezomib, and dexamethasone, are approved by the FDA. They ... approved by the FDA for the treatment of multiple myeloma. Lenalidomide is approved for use with dexamethasone for patients with multiple ...

    Clinical Trial last updated 05/23/2016 - 3:45pm.